CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Chloroquine phosphateWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug2252 Sham iTBS to the dlPFC Wiki 0.58
drug2033 Real cTBS to the vmPFC Wiki 0.58
drug2034 Real iTBS to the dlPFC Wiki 0.58
drug2251 Sham cTBS to the vmPFC Wiki 0.58
drug2457 Telemedicine Wiki 0.33

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D016739 Behavior, Addictive NIH 0.58
D014029 Tobacco Use Disorder NIH 0.41
D019966 Substance-Related Disorders NIH 0.22
D007239 Infection NIH 0.03

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0030858 Addictive behavior HPO 0.58

There are 3 clinical trials

Clinical Trials

1 A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam

COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent COVID-19 or therapeutic agent to treat COVID-19. This clinical trial is designed to evaluate potential therapeutics for the treatment of hospitalized COVID-19. We hypothesis that chloroquine slows viral replication in patients with COVID-19, attenuating the infection, and resulting in more rapid declines in viral load in throat swabs. This viral attenuation should be associated with improved patient outcomes. Given the enormous experience of its use in malaria chemoprophylaxis, excellent safety and tolerability profile, and its very low cost, if proved effective then chloroquine would be a readily deployable and affordable treatment for patients with COVID-19. The study is funded and leaded by The Ministry of Health, Vietnam.

NCT04328493 SARS-CoV-2 Infection COVID-19 Drug: Chloroquine phosphate
MeSH:Infection

Primary Outcomes

Description: Viral presence will be determined using RT-PCR to detect SARS-CoV-19 RNA. Throat/nose swabs for viral RNA will be taken daily while in hospital until there have at least 2 consecutive negative results . Virus will be defined as cleared when the patient has had ≥2 consecutive negative PCR tests. The time to viral clearance will be defined as the time following randomization to the first of the negative throat/nose swabs.

Measure: Viral clearance time

Time: Up to 56 days post randomization

Secondary Outcomes

Description: The time since randomization to discharge between study groups

Measure: Lengh of hospital stay

Time: Up to 56 days post randomization

Description: The number of ventilator free days over the first 28 days of treatment

Measure: Ventilator free days

Time: first 28 days

Description: The number of oxygene free days over the first 28 days of treatment

Measure: Oxygene free days

Time: first 28 days

Description: The time to (all-cause) death following over the first 7, 10, 14, 28 and 56 days since randomization

Measure: Time to death

Time: first 7, 10, 14, 28 and 56 days since randomization

Description: The rates of serious adverse events, rates of grade 3 or 4 adverse events

Measure: Adverse events

Time: Over the first 28 days (due to the prolonged half-life of Chloroquine)

Description: Time since randomization to the first defervescence day

Measure: fever clearance time

Time: Up to 56 days post randomization

Description: WHO Ordinal outcome scale for COVID-19

Measure: Ordinal outcome scale

Time: Up to 56 days post randomization

Description: Development of ARDS defined by the Kigali criteria

Measure: Development of ARDS

Time: Up to 56 days post randomization

2 Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications

The aim of the study is to evaluate whether the therapy with chloroquine phosphate (CQ, in combination with telemedical approach) in addition to standard care is effective and safe in reducing composite endpoint of COVID-19-related hospitalization or all cause death, in ambulatory patients with SARS-SoV-2 infection at particular risk of serious complications due to advanced age and/or comorbid conditions (in comparison with subjects not treated with CQ but receiving standard care and supervised telemedically).

NCT04331600 COVID-19 Drug: Chloroquine phosphate Other: Telemedicine

Primary Outcomes

Description: Composite endpoint of COVID-19-related hospitalization or all-cause death

Measure: COVID-19-related hospitalization or all-cause death

Time: 15 days

Secondary Outcomes

Description: Decrease in self-reported symptoms of novel coronavirus infection. Non-dichotomous symptoms (e.g. syncope is dichotomous - yes or no) such as dyspnoea will be self-evaluated by patients using the 0-3 scale with the severity increasing with the punctation (0-no symptoms, 1-mild symptoms, 2-moderate symptoms, 3-severe symptoms).

Measure: Decrease in COVID-19 symptoms

Time: 15 days and 42 days

Description: Based on X-ray, microbiology and laboratory results

Measure: Development of pneumonia

Time: 42 days

Description: Acute respiratory distress syndrome, bacterial infection, shock, sepsis, etc

Measure: Development of coronavirus infection-related complications

Time: 42 days

3 Efficacy of Chloroquine Phosphate Prophylactic Use in First-line Health Personnel Exposed to COVID-19 Patients

The primary objective of this study is to evaluate the efficacy and security of chloroquine phosphate prophylactic use for reducing the risk of infection by severe acute respiratory syndrome coronavirus-2 in Health Care Workers exposed to COVID-19 patients.

NCT04443270 COVID-19 Drug: Chloroquine phosphate

Primary Outcomes

Description: Prior to the participation of each health worker, a pharyngeal exudate sample will be taken with a swab. RNA will be obtained by applying severe acute respiratory syndrome coronavirus-2 real time polymerase chain reaction kit, using specific oligonucleotides in polymerase chain reaction.

Measure: Negative Polymerase Chain Reaction assay at day 0

Time: Day 0

Description: A pharyngeal exudate sample will be taken with a swab. RNA will be obtained by applying severe acute respiratory syndrome coronavirus-2 real time polymerase chain reaction kit, using specific oligonucleotides in polymerase chain reaction.

Measure: Polymerase Chain Reaction assay at day 60

Time: Day 60

Secondary Outcomes

Description: Ordinal Scale for Clinical Improvement according the "World Health Organization R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis" will apply at baseline and 30-day follow-up as follows: No clinical or virological evidence of infection = 0 No limitation of activities = 1 Limitation of activities = 2 Hospitalized, no oxygen therapy = 3 Oxygen by mask or nasal prongs = 4 Non-invasive ventilation or high-flow oxygen = 5 Intubation and mechanical ventilation - Score = 6 Ventilation + additional organ support-pressors, renal replacement therapy, extracorporeal membrane oxygenation = 7 Death = 8

Measure: Clinical improvement related to COVID-19

Time: Baseline (day 0) and 30-day follow up

Description: Ordinal Scale for Clinical Improvement according the "World Health Organization R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis" will apply at baseline and 30-day follow-up as follows: No clinical or virological evidence of infection = 0 No limitation of activities = 1 Limitation of activities = 2 Hospitalized, no oxygen therapy = 3 Oxygen by mask or nasal prongs = 4 Non-invasive ventilation or high-flow oxygen = 5 Intubation and mechanical ventilation - Score = 6 Ventilation + additional organ support-pressors, renal replacement therapy, extracorporeal membrane oxygenation = 7 Death = 88

Measure: Clinical improvement related to COVID-19

Time: From 30-day to 60-day follow-up

Description: An EKG will be performed to measure QT interval at baseline and 30-day follow-up. The EKG follows the standards and guidelines established by the Centro Médico Nacional "20 de Noviembre."

Measure: Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic Use

Time: Baseline (day 0) and 30-day follow up

Description: An EKG will be performed to measure QT interval at 60-day follow-up. The EKG follows the standards and guidelines established by the Centro Médico Nacional "20 de Noviembre."

Measure: Heart rhythm negative adverse event related to the Chloroquine Phosphate Prophylactic

Time: From 30-day to 60-day follow-up

Description: According to the National Committee for Epidemiological Surveillance (CONAVE) in Mexico, COVID-19 symptomatic onset rate defined as the presence of cough, fever or headache during the last 7 days, accompanied at least one of the following symptoms: dyspnea, arthralgia, myalgia, odynophagia / pharyngeal burning, rhinorrhea, conjunctivitis or chest pain.

Measure: COVID-19 symptomatic onset rate

Time: From baseline (day 0) to 60-day follow up

No related HPO nodes (Using clinical trials)